CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure

Stock News

08/07

CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.

On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.

Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1163799508"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163799508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163799508?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163799508","market":"fut","top_or_hot":-1,"title":"CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure","media":"Stock News","content":"<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B (02171) Surges Over 4% as CT1190B Gets IND Nod for R/R LBCL Patients After Second-Line Failure\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-08-07 10:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><b>CARSGEN-B</b> (<b>02171</b>) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.<br><br>On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.<br><br>Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on <b>CARSGEN-B</b>'s proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1163799508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163799508","pubTimestamp":1786071162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","KCAI":"KraneShares China Alpha Index ETF","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","VXUS":"国际股票ETF-Vanguard","BK1585":"昨日强势股","02171":"科济药业-B"},"translate_title":"CARSGEN-B (02171) 飙升超过 4%，CT1190B 在二线失败后获得 IND Nod 用于 R/R LBCL 患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"VXUS":1,"KCAI":1},"content_text":"CARSGEN-B (02171) extended its rally, climbing more than 4% in Monday's trading session. As of the latest update, the stock was up 4.03% to HK$15.48, with trading volume reaching HK$21.99 million.On August 7, the company announced that CT1190B, a universal CAR-T cell therapy targeting both CD19 and CD20, has received Investigational New Drug (IND) approval from China's National Medical Products Administration. The therapy is indicated for treating patients with relapsed or refractory large B-cell lymphoma (R/R LBCL) who have failed at least two prior lines of standard therapy.Results from the investigator-initiated trial (IIT) of CT1190B were presented as a poster at the 2026 European Hematology Association Congress. Developed on CARSGEN-B's proprietary THANK-u Plus® platform, CT1190B is currently undergoing IIT for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}